- Home
- HLVX vs SKYE Comparison
HLVX vs SKYE Comparison
Compare HLVX & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HLVX
- SKYE
- Stock Information
- Founded
- HLVX 2020
- SKYE 2012
- Country
- HLVX United States
- SKYE United States
- Employees
- HLVX N/A
- SKYE N/A
- Industry
- HLVX Biotechnology: Pharmaceutical Preparations
- SKYE Biotechnology: Pharmaceutical Preparations
- Sector
- HLVX Health Care
- SKYE Health Care
- Exchange
- HLVX Nasdaq
- SKYE Nasdaq
- Market Cap
- HLVX 83.7M
- SKYE 73.4M
- IPO Year
- HLVX 2022
- SKYE N/A
- Fundamental
- Price
- HLVX $1.97
- SKYE $4.32
- Analyst Decision
- HLVX Hold
- SKYE Buy
- Analyst Count
- HLVX 5
- SKYE 6
- Target Price
- HLVX $2.33
- SKYE $16.60
- AVG Volume (30 Days)
- HLVX 436.7K
- SKYE 1.9M
- Earning Date
- HLVX 08-07-2025
- SKYE 08-08-2025
- Dividend Yield
- HLVX N/A
- SKYE N/A
- EPS Growth
- HLVX N/A
- SKYE N/A
- EPS
- HLVX N/A
- SKYE N/A
- Revenue
- HLVX N/A
- SKYE N/A
- Revenue This Year
- HLVX N/A
- SKYE N/A
- Revenue Next Year
- HLVX N/A
- SKYE N/A
- P/E Ratio
- HLVX N/A
- SKYE N/A
- Revenue Growth
- HLVX N/A
- SKYE N/A
- 52 Week Low
- HLVX $1.34
- SKYE $1.14
- 52 Week High
- HLVX $15.25
- SKYE $8.26
- Technical
- Relative Strength Index (RSI)
- HLVX 58.49
- SKYE 81.18
- Support Level
- HLVX $1.83
- SKYE $2.12
- Resistance Level
- HLVX $1.95
- SKYE $2.22
- Average True Range (ATR)
- HLVX 0.08
- SKYE 0.35
- MACD
- HLVX 0.00
- SKYE 0.20
- Stochastic Oscillator
- HLVX 60.78
- SKYE 84.03
About HLVX HilleVax Inc.
HilleVax Inc is a clinical-stage biopharmaceutical company. The company is focused on developing and commercializing novel vaccines. The firm's initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection.
About SKYE Skye Bioscience Inc. Common Stock
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.